SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service. The new service offering, which will be available from the beginning of 2018, will allow the two companies to cater to virtually all customer needs for viral vector services, from initial vector engineering and development to GMP production. As part of the collaboration, SIRION Biotech will pro...